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Objectives: To assess the prevalence of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV)
infections and co-infections among injecting drug users (IDUs) in Tehran.
Methods: A sample of 899 IDUs (861 male and 38 female) was recruited in Tehran from treatment
and harm reduction facilities and from drug user hangouts in public areas in equal proportions.
ELISA testing for HIV, HCVantibody (HCV-Ab), hepatitis B surface antigen (HBsAg), and hepatitis B
core antibody (HBcAb) was carried out. Positive HIV tests were rechecked by Western blot.
Results: The prevalence of HIV was 10.7%, HCV infection was 34.5%, and past or current HBV
infection was 50.7%. Infection with all three viruses was seen in 6.5% (95% confidence interval 4.9—
8.2) of participants. HIV/HCV, HIV/HBV, and HBV/HCV co-infections were seen in 8.7%, 7.8%, and
21.0% of participants, respectively. The rate of HCV infection among HIV-positive cases was
significantly higher than inHIV-negative IDUs (80.6%vs. 28.7%,p < 0.0001). Therewas no significant
association between these infections and co-infections with gender and source of sampling.
Conclusion: In general, co-infection with these three blood-borne viruses is common among IDUs.
Since co-infection increases the morbidity and mortality of all infections, the observed level of
co-infection in the high number of IDUs in Iran necessitates a serious comprehensive response.
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According to the current estimate for the year 2007, 15.9
million people are injecting drug users (IDUs) worldwide.1 It
has also been estimated that 180 000 IDUs live in Iran,1 whichPublished by Elsevier Ltd. All rights reserved.
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injection drug use, it appears that injecting drug use has had
a more rapidly increasing prevalence rate during the past
decade.2
IDUs make up a population group that shows a high pre-
valence of blood-borne infections, mainly HIV, hepatitis B
virus (HBV), and hepatitis C virus (HCV).3 Co-infection with
HIVand HCV has repeatedly been reported among IDUs. There
is also evidence of HBV co-infection with other blood-borne
infections.4,5
In Iran, the prevalences of HIV, HCV, and HBV infections
in the general population have been estimated to be
<0.2%,6 <1%,7 and <5%,8 respectively. Iran is a country
with a concentrated epidemic of HIV. The current data in
Iran indicate that IDUs are the most affected population
and have contributed to approximately 67% of identified
cases of HIV/AIDS.6 Risk behaviors are quite common
among IDUs, although different groups of IDUs have dif-
ferent risk profiles.9 Surveys have been conducted on
various high-risk groups in the country, but so far there
has been no study on co-infections with the three impor-
tant blood-borne infections among IDUs. In addition, the
data already available do not give a wide understanding of
the epidemiological specifications of these diseases. Iran
adopted a harm reduction policy in 2002. Expansion of the
harm reduction interventions started after the design of
the national five-year program (2002—2007) on harm
reduction. In the year 2007, over a six-month period,
1 400 000 needles and syringes were distributed to IDUs
through 120 drop-in centers (DICs) and 150 outreach
teams. Also, around 22 000 drug users were on opioid
substitution treatment in mid-2007.10 As rapid changes
in the prevalence of blood-borne infections can occur
among high-risk groups, continuous surveillance and
repeated studies are needed to monitor trends and the
effects of large-scale harm reduction interventions.
The research reported in this paper is a part of a larger
study conducted on the characteristics, risk behaviors, infec-
tions and their risk factors, and service use of IDUs in Tehran,
the capital city of Iran. We present herein the results of
testing for HIV, HCV, HBV, and co-infections in this sample.
Methods
Study design and participants, and data
collection
A cross-sectional study was carried out on 904 volunteer
current IDUs who were selected from drug treatment centers
and from the community during June 2006—March 2007. The
study included an interview and blood testing. However, five
of the interviewees refused participation in the blood test-
ing. Therefore, 899 IDUs participated in both parts of the
study. Drug users who had used drugs by the injection route in
the last two months were regarded as current IDUs.
The community sample was selected from five areas of
Tehran with high rates of drug-related risk behaviors, with
purposive sampling using ethnographic observations in public
places, peer referral, and snowballing. The other sample was
selected from three drug treatment centers and two DICs
located in different well-known areas with high rates of drug-related risk behaviors in Tehran. The treatment centers
provide methadone maintenance treatment (MMT) and DICs
provide mainly other types of harm reduction interventions
including a needle and syringe program (NSP). Cases were
selected based on consecutive admission over the study time
period. Apart from the current course of treatment, it was
required that the subject should not have been in the same
program or any other treatment program during the last six
months.
Fieldwork, including interview and blood sampling, was
carried out by experienced drug therapists and outreach
workers after a short training course, which included training
on the questionnaire and the transferring of blood samples to
the laboratory.
The use of free-of-charge health services including drug
treatment was offered as an incentive. IDUs could also
receive the results of their tests on presentation of their
code number. For those who received the results of their
tests, post-test counseling was also offered.
Testing
Participant blood samples were tested for HIV (anti-HIV Tetra
ELISA, Biotest Co., Germany), HCV antibody (HCV-Ab ELISA,
DRG Co., Germany), hepatitis B core antibody (Anti-HBc EIA
WELL, Radim, Italy), and hepatitis B surface antigen (HBsAg
IEMA WELL, Radim, Italy), and also VDRL (venereal disease
research laboratory; Immutrep VDRL Antigen, Omega Diag-
nostic, UK). Positive ELISA tests for HIV were confirmed using
a Western blot test (HIV Blot 2.2, MP Biomedicals, France). A
positive result either for hepatitis B surface antigen (HBsAg)
or for hepatitis B core antibody (HBcAb) was considered as
‘past or current HBV infection’. All positive and borderline
samples for HBsAg, HBcAb, and HCV antibody (HCV-Ab) were
retested by the same method. We excluded samples that
showed a repeated borderline result. All tests were done at
the Keyvan Laboratory, which is one of the few reference
laboratories for Western blot testing authorized by the Min-
istry of Health.
Ethical issues
The research protocol was approved by the ethics committee
of Tehran University of Medical Sciences in Iran. Participation
in the study was on a voluntary basis after obtaining informed
consent. All efforts were made to guarantee privacy during
interviews and confidentiality. A de-linkedmethod for testing
was carried out. Instead of a block for the patient’s name,
each questionnaire had an identification code, which was
used for laboratory results as well. For participants recruited
from treatment centers, the option of refusing participation
in the study or refusing to answer any question was offered,
without affecting their service use.
Statistical analysis
Statistical analysis was done using SPSS for windows (version
16.0, 2007; SPSS Inc., Chicago, IL, USA). Univariate analysis
using the Chi-square or Fisher’s exact tests was done to assess
the association between infection status, sex, and source of
study sample.
Figure 2 The prevalence of HIV, past or current HBV infections,
and co-infections in IDUs by HCV infection status in Tehran
(N = 860).
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A total of 899 IDUs (861 male and 38 female) participated in
the study. Study participant age ranged from 16 to 65 years,
with a mean age ( standard deviation) of 33.87 ( 9.45)
years. At the time of interview, more than a third (39.1%) of
the respondents were homeless or resided in a room rented
on a daily basis, residential community, drug treatment
institution, or shelter. Around 64% of participants were
unemployed.
The prevalence of HIV was 10.7%, HCV was 34.5%, and past
or current HBV was 50.7%. The result of HBV testing was
borderline or the sample was insufficient for HBV testing in 35
(3.5%) cases. HBsAgwas detected in 30.9% and anti-HBc IgG in
29.1% of 864 cases. We also tested the sample by the VDRL
test and found positive results in four (0.5%) of the partici-
pants, from whom three were also positive for HBV and one
for HCV; none tested positive for HIV.
In 65% of tested participants, at least one of the three viral
infections was seen (95% confidence interval (CI) 61.8—68.2)
and 6.5% (95% CI 4.9—8.2) of cases were infected with all
three viruses. HIV/HCV co-infection was seen in 8.7% (95% CI
6.9—10.6) of participants. HIV/HBV co-infection was seen in
7.8% (95% CI 6—9.6) and finally HBV/HCV co-infection
affected 21.0% (95% CI 18.3—23.7) of cases.
The rate of HCV and HBV infections among HIV-positive
cases was significantly higher than in HIV-negative IDUs (HCV
80.6% vs. 28.7%, p < 0.0001 and HBV 72% vs. 48.4%,
p < 0.0001). The rate of HIV and HBV infections among
HCV-positive cases was significantly higher than in HCV-nega-
tive IDUs as well (HIV 25.4% vs. 3.2%, p < 0.0001 and HBV
61.4% vs. 45.5%, p < 0.0001). Also, the rate of HIV and HCV
infections among HBV-positive cases was significantly higher
than in HBV-negative IDUs (HIV 15.3% vs. 6.2%, p < 0.0001
and HCV 41.3% vs. 27%, p < 0.0001). These results are shown
in Figures 1—3. All other differences shown in Figures 1—3 are
also statistically significant ( p < 0.0001). Detailed results on
the prevalences of the three infections in both sexes, as well
as in the community and treatment/DIC samples are shown in
Table 1. There was no significant association between these
infections and co-infections with gender and source of sam-
pling.Figure 1 The prevalence of HCV, past or current HBV infec-
tions, and co-infections in IDUs by HIV infection status in Tehran
(N = 860).Discussion
A geographical and temporal variability is common in viral
infections.11 However, most previous studies on co-infections
have been reported from only a few countries. Therefore,
information from a variety of IDU populations would be useful
in understanding the correlation between these infections,
as well as the correlated factors in the transmission of each of
them. To the best of our knowledge this study covers a wider
spectrum of epidemiologic indicators of blood-borne co-
infections among IDUs and has a relatively larger sample size
than previous studies; it also presents the results from a
developing country where a serious injection drug use pro-
blem exists.
Prevalence of HIV, HCV, and HBV infections
Since 1995, various studies on blood-borne infections have
been conducted in Iran among IDUs in different cities and
different settings, such as IDUs in drug treatment centers,
prisons and in communities. The results have ranged from
zero to 23.2% for HIV and from 11.2% to 89.5% for hepatitis C
infections.12—24 Our study, with the highest ever sample sizeFigure 3 The prevalence of HIV, HCV infections, and co-infec-
tions in IDUs by HBV infection status in Tehran (N = 860).
Table 1 The prevalence of HIV, Hepatitis C, past or current Hepatitis B and Syphilis & viral co-infections in IDUs, by sex and source
of sampling in Tehran






















HIV 899 96 (10.7) 861 92 (10.7) 38 4 (10.5) 448 52 (11.6) 451 44 (9.8)
HCV 895 309 (34.5) 859 293 (34.1) 36 16 (44.4) 445 160 (36) 450 149 (33.1)
HBV 864 438 (50.7) 827 421 (50.9) 37 17 (45.9) 429 217 (50.6) 435 221 (50.8)
VDRL 887 4 (0.5) 849 3 (0.4) 38 1 (2.6) 443 0 (0) 444 4 (0.9)
HIV/HCV 895 78 (8.7) 859 75 (8.7) 36 3 (8.3) 445 37 (8.3) 450 41 (9.1)
HIV/HBV 864 67 (7.8) 827 64 (7.7) 37 3 (8.1) 429 36 (8.4) 435 31 (7.1)
HCV/HBV 860 181 (21) 825 171 (20.7) 35 10 (28.6) 426 92 (21.6) 434 89 (20.5)
All three viruses 860 56 (6.5) 825 53 (6.4) 35 3 (8.6) 426 27 (6.3) 434 29 (6.7)
Figure 4 Venn diagram of HIV/HCV/HBV co-infections (%)
among IDUs in Tehran, Iran (N = 860).
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HCV and HIV infections among IDUs compared to those found
in studies conducted in recent years in Tehran.12,17,21—24 This
finding is in line with the decreasing trend in newly identified
HIV/AIDS cases by the National Surveillance System,25 and
might be a result of the scaling-up of harm reduction inter-
ventions including NSP and MMT in Tehran since 2003; this
needs further investigation.
Diverse results have been reported on HBV infection in
IDUs, perhaps due to the different serum markers used in the
different studies. Some studies have reported the results of
HBsAg testing and others have used different tests such as
HBcAb, hepatitis B e antigen (HBeAg), and even HBV-DNA.
Reported rates range from 6%26 to 83.4%,4 depending on the
markers tested as well as the settings from which the IDUs
have been selected. To the best of our knowledge, in all
studies reported from Iran so far the only tested marker has
been HBsAg, with positive results ranging from 2.9% to
10%13,15,22,27 in IDUs, except for one study in which the
infection rate in 28 prisoner IDUs was reported to be
25.9%.20 However, the higher rate of past or current HBV
infection found in our study necessitates further exploration.
It should be noted that the specificity of the utilized tests for
HBsAg and HBcAb have been reported to be 99.8% and 99.7%,
respectively. An explanation for the high prevalence is that in
Iran, in the nationwide health intervention, newborns have
only been vaccinated against hepatitis B since 1992, and only
1.2% of IDUs in our sample were able to recall a history of
three doses of hepatitis vaccination, on a voluntary basis.
Co-infections and the route of transmission
Hagan et al. have summarized a number of studies on the
prevalence of co-infections in IDUs, most of which were on
HIV-positive patients in clinical settings. In these samples,
the prevalence of HCV infection has been high, at between
52% and 92%. A few other studies have examined HIV pre-
valence among HCV-positive IDUs and have reported results
of from 8% to 50%.11 Our study is consistent with these
results, although in the medium to high range of the reported
spectrum. A high rate of HCV co-infection (80.6%) among HIV-
positive IDUs in our sample is an indicator that HIV is more
probably being transmitted via infected injection equipment
than by the sexual route. However, as 19.4% of HIV-positive
IDUs were negative for HCV, and there is a high degree ofunsafe sex among Iranian IDUs,28 it seems that sexual beha-
vior is also contributing to the HIV epidemic among IDUs. This
has been a concern in HIV epidemics among IDUs in other
countries as well.29—31 However, the test for syphilis showed a
very low rate compared to the rates of 1% to 13% among IDUs
in other Asian countries,32—35 and is compatible with the
result (zero from 19 IDUs) of the only study from Iran,13
although VDRL alone is not an adequate indicator for sexual
transmission of HIV.
There are controversies surrounding the relationship
between HBV infection with HIV and HCV infections, as it
has been reported from several Asian and African countries,36
as well as from Spain,4,5 and in a systematic review from
China37 that HBV infection has no significant relationship with
HIV and HCV positivity. However, our study showed that HBV
infection was significantly associated with HIVand HCV infec-
tions. Figure 4 schematically presents the high degree of
association between these three infections.
Infections and co-infections among female IDUs
There is evidence that in Iran less than 3% of IDUs are
female.38 In our sample, 4.2% of the participants were
e32 A. Rahimi-Movaghar et al.female. This is the first study in Iran reporting infections and
co-infections among 38 female IDUs and comparing the pre-
valence of infections between male and female IDUs. A few
studies have focused on HIV prevalence among female prison-
ers and found zero prevalence.18,39,40 This is why vulnerable
groups of women have so far not been considered at high risk
for HIV in Iran. However, our study showed no significant
difference between the two sexes in infection with the
studied viruses or co-infections, and suggests a similar degree
of risk for women as for men. It appears that more studies are
needed especially on HCV prevalence, which might be higher
among female IDUs.
Infections and co-infections among different
samples of IDUs
There is little evidence of differences in blood-borne infec-
tions and co-infections between community samples and
other sources of sampling of IDUs such as treatment centers.
Comparisons can only be made for different studies with
various sources of sampling. There are various reports on
HIV infection in IDUs showing a prevalence of from 0.5% in
those receiving treatment and needle and syringes services26
to 43.1% in those recruited from prisons.4 In studies from
Iran, the lowest rate of zero27 has repeatedly been reported
in IDUs recruited from treatment centers in small cities. The
highest rate of 23.2%, however, has been reported in IDUs
recruited from the community12 and harm reduction services
in metropolitan Tehran.
In studies on HCV infection, the results from other coun-
tries also vary according to the source of sampling, from low
rates such as 27% in new IDUs recruited from the community41
to 91.7% in prisoners.4 Similar results have been reported
from Iran, with an HCV prevalence rate of 11—30% from those
recruited from treatment centers15,17,27 to 80—90% in pris-
oner IDUs.13,14,17
In our study, there was no significant difference between
the prevalence of infections and co-infections from the
community sample compared to the sample from the treat-
ment and harm reduction services. This suggests that the two
groups are not separated and have a dynamic interaction and
might have a similar nature. Previous experiences and obser-
vations show that most drug users including IDUs enter
treatment several times in their lifetime, and shift from
one setting to another.28
Limitations
This study was conducted in areas of Tehran that have been
shown in previous studies to have a higher prevalence of
drug-related high-risk behaviors. This selection was made in
order to reach a higher number of IDUs and the results might
not be representative of the average Iranian urban neighbor-
hood.
Conclusions
In general, co-infection with the three blood-borne viruses
(HIV, HBV and HCV) is common among IDUs and they are
greatly at risk for all three infections and co-infections.
Results of 65% prevalence of at least one of the three infec-tions and 6.5% of infection with all three viruses show a
critical risk profile for IDUs in Iran. Given the fact that co-
infection of HIV with hepatitis C and B viruses increases the
morbidity and mortality and changes the natural history of
all infections, the observed magnitude necessitates a rapid
and serious comprehensive response, addressing all infec-
tions simultaneously.
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